Skip to main content
OpenTrials
Completed

NCT Number: NCT04020861

Photobiomodulation Therapy and Transcutaneous Electrical Nerve Stimulation on Chronic Neck Pain Patients

This study evaluates the efficacy isolated and combinaded of photobiomodulation therapy with low level laser therapy and the transcutaneous electrical nerve stimulation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Neck Pain Chronic Pain Neck Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Federal University São Carlos

São Carlos, São Paulo, 13565-905, Brazil

About this study

Non-specific chronic neck pain patients will be treated with low-level laser therapy and/or trancutaneous electricam nerve stimulation. They will receive 10 sessions of treatment. Before and after the treatment physical measures and psychosocial factors will be evaluted to verificy the efficay these electrophysical agents.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with non-specific chronic neck pain, defined as pain or discomfort in the posterior cervical region between the superior nuchal line and the first thoracic spinous process and / or shoulder girdle;
  • Neck pain for at least 3 months;
  • Neck Disability Index (NDI) score of 5 points or higher;
  • Numeric Rating Scale (NRS) score of 3 or higher to pain intensity;
  • Aged between 18 and 65 years;
  • Men and women

Exclusion criteria

  • Neck pain associated with nerve root compromise (measured by clinical examination of dermatomes, myotomes and reflexes);
  • Previous spinal surgery;
  • Patients treated with physical therapy for neck pain in the last 3 months previous the study;
  • Severe spinal disorders such as fractures, tumors, inflammatory and infectious diseases;
  • Any contraindication to low level laser therapy or transcutaneous electrical nerve stimulation;
  • Rheumatic, metabolic, neurological or cardiopulmonary diseases;
  • Patients who require artificial cardiac pacemakers;
  • Skin diseases, mainly at the current application site;
  • Tumors or cancer historic in the last 5 years;
  • Pregnancy;
  • If the patient started any physical activity in the last 2 weeks.

Treatment and study plan

Active PBM

Device

To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.

Active TENS

Device

To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.

PLACEBO PBM

Device

In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.

Placebo TENS

Device

To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.

Primary outcomes

  1. Pain intensity: Numerical Rating Scale (Pain NRS)

    Time frame: 2 weeks after randomization

    Pain intensity will be evaluated using an 11-point (0-10) Numerical Rating Scale (Pain NRS), which is a simple and easy-to-use measuring scale that consists of a sequence of numbers from zero to 10, in which zero represents "no pain" and 10 represents "the worst pain imaginable". The pain evaluation will be carried out verbally with the patient reporting the pain intensity.

Secondary outcomes

  1. Pain intensity: Numerical Rating Scale (Pain NRS)

    Time frame: 6 weeks after randomization

    Pain intensity will be evaluated using an 11-point (0-10) Numerical Rating Scale (Pain NRS), which is a simple and easy-to-use measuring scale that consists of a sequence of numbers from zero to 10, in which zero represents "no pain" and 10 represents "the worst pain imaginable". The pain evaluation will be carried out verbally with the patient reporting the pain intensity.

  2. Pain intensity at movement: Numerical Rating Scale (Pain NRS)

    Time frame: 2 weeks after randomization

    Pain intensity will be evaluated during the cervical movements of flexion, extension, right and left lateral inclination and right and left rotation, using an 11-point (0-10) Numerical Rating Scale (Pain NRS)

  3. Neck disability

    Time frame: 2 weeks after randomization

    Neck disability will be evaluated using neck disability index (NDI) that consists of a 10-item questionnaire that assess the impact of pain on daily activities using a score from 0 to 5 for each section, with higher values indicating more severe impact.

  4. Cervical range of motion

    Time frame: 2 weeks after randomization

    Cervical range of motion will be measured with a fleximeter

  5. Pressure Pain Threshold

    Time frame: 2 weeks after randomization

    Pressure pain threshold (PPT) in the neck, shoulder girdle and anterior tibialis muscle will be measured using a Somedic Type II pressure algometer

  6. Pain temporal summation (TS)

    Time frame: 2 weeks after randomization

    Temporal summation (TS) will be induced by a pressure algometer. Ten (10) stimuli with a pressure of 40 kPa/s of the mean value of algometry performed prior on the upper trapezius. Patients will be asked about their pain using NRS at the first, fifth and tenth stimulus.

  7. Conditioned pain modulation (CPM)

    Time frame: 2 weeks after randomization

    The conditioned stimulus for eliciting CPM will be the cold pressor test (Cold Water Bath test to the hand) and the test stimulus will be the assessment of PPT on the upper trapezius muscle.

  8. Depressive symptoms

    Time frame: 2 weeks after randomization

    The depressive symptoms will be performed using Beck Depression Inventory (BDI). The scale consists of items including symptoms and attitudes whose intensity range from neutral to a maximum level of severity, rated from 0 to 3.

  9. Pain catastrophizing

    Time frame: 2 weeks after randomization

    Pain catastrophizing will be performed with Pain Catastrophizing Scale (PCS) - The PCS is a self-administered questionnaire that consists of 13 items to assess catastrophizers. The items are rated on a 5-point Likert-type scale in which both intensity and frequency information are represented, with the following five levels of response for each Likert item: (0) not at all, (1) to a slight degree, (3) to a moderate degree, (4) to a great degree, (5) and all the time. The total score is computed by summation of all items and the total score ranges from 0 to 52 points. Higher scores indicate greater catastrophic pain.

  10. Change in patient perception of quality of life:12-Item Short-Form Health Survey (SF-12)

    Time frame: 2 weeks after randomization

    The quality of life will be performed using 12-Item Short-Form Health Survey (SF-12) version 2 questionnaire. This is a self-report measure that assesses physical (Physical Component Summary - PCS) and mental (Mental Component Summary - MCS) health on a scale of 0 - 100. Higher scores represent better levels of quality of life.

  11. Analgesic intake

    Time frame: 2 weeks after randomization

    Anlgesic intake will be evaluated asking to the patients all analgesic medications (opioids and non-opioids) taken one week prior to evaluation and during the treatment.

  12. Global perceived effect (GPE)

    Time frame: 2 weeks and 6 weeks after randomization

    Global perceived effect will be evaluated by an 11 - point (- 5 to + 5) Global Perceived Effect Scale. It consists of an 11-point scale that ranges from -5 (vastly worse) through 0 (no change) to 5 (completely recovered).

Sponsors and collaborators

Lead sponsor

Universidade Federal de Sao Carlos

Other

Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 16, 2019
Registry last updated
Sep 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.